Literature DB >> 20018889

Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation.

Jessica W Wu1, Leonid Breydo, J Mario Isas, Jerome Lee, Yurii G Kuznetsov, Ralf Langen, Charles Glabe.   

Abstract

Soluble amyloid oligomers are potent neurotoxins that are involved in a wide range of human degenerative diseases, including Alzheimer disease. In Alzheimer disease, amyloid beta (Abeta) oligomers bind to neuronal synapses, inhibit long term potentiation, and induce cell death. Recent evidence indicates that several immunologically distinct structural variants exist as follows: prefibrillar oligomers (PFOs), fibrillar oligomers (FOs), and annular protofibrils. Despite widespread interest, amyloid oligomers are poorly characterized in terms of structural differences and pathological significance. FOs are immunologically related to fibrils because they react with OC, a conformation-dependent, fibril-specific antibody and do not react with antibodies specific for other types of oligomers. However, fibrillar oligomers are much smaller than fibrils. FOs are soluble at 100,000 x g, rich in beta-sheet structures, but yet bind weakly to thioflavin T. EPR spectroscopy indicates that FOs display significantly more spin-spin interaction at multiple labeled sites than PFOs and are more structurally similar to fibrils. Atomic force microscopy indicates that FOs are approximately one-half to one-third the height of mature fibrils. We found that Abeta FOs do not seed the formation of thioflavin T-positive fibrils from Abeta monomers but instead seed the formation of FOs from Abeta monomers that are positive for the OC anti-fibril antibody. These results indicate that the lattice of FOs is distinct from the fibril lattice even though the polypeptide chains are organized in an immunologically identical conformation. The FOs resulting from seeded reactions have the same dimensions and morphology as the initial seeds, suggesting that the seeds replicate by growing to a limiting size and then splitting, indicating that their lattice is less stable than fibrils. We suggest that FOs may represent small pieces of single fibril protofilament and that the addition of monomers to the ends of FOs is kinetically more favorable than the assembly of the oligomers into fibrils via sheet stacking interaction. These studies provide novel structural insight into the relationship between fibrils and FOs and suggest that the increased toxicity of FOs may be due to their ability to replicate and the exposure of hydrophobic sheet surfaces that are otherwise obscured by sheet-sheet interactions between protofilaments in a fibril.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018889      PMCID: PMC2825401          DOI: 10.1074/jbc.M109.069542

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

2.  Template-assisted filament growth by parallel stacking of tau.

Authors:  Martin Margittai; Ralf Langen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

3.  3D structure of Alzheimer's amyloid-beta(1-42) fibrils.

Authors:  Thorsten Lührs; Christiane Ritter; Marc Adrian; Dominique Riek-Loher; Bernd Bohrmann; Heinz Döbeli; David Schubert; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

4.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils.

Authors:  Aneta T Petkova; Richard D Leapman; Zhihong Guo; Wai-Ming Yau; Mark P Mattson; Robert Tycko
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

6.  Prefibrillar amyloid aggregates could be generic toxins in higher organisms.

Authors:  Serena Baglioni; Fiorella Casamenti; Monica Bucciantini; Leila M Luheshi; Niccolò Taddei; Fabrizio Chiti; Christopher M Dobson; Massimo Stefani
Journal:  J Neurosci       Date:  2006-08-02       Impact factor: 6.167

7.  Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Authors:  Ganesh M Shankar; Shaomin Li; Tapan H Mehta; Amaya Garcia-Munoz; Nina E Shepardson; Imelda Smith; Francesca M Brett; Michael A Farrell; Michael J Rowan; Cynthia A Lemere; Ciaran M Regan; Dominic M Walsh; Bernardo L Sabatini; Dennis J Selkoe
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

Review 8.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

9.  Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer.

Authors:  Rakez Kayed; Anna Pensalfini; Larry Margol; Yuri Sokolov; Floyd Sarsoza; Elizabeth Head; James Hall; Charles Glabe
Journal:  J Biol Chem       Date:  2008-12-18       Impact factor: 5.157

10.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

View more
  67 in total

1.  Atomic view of a toxic amyloid small oligomer.

Authors:  Arthur Laganowsky; Cong Liu; Michael R Sawaya; Julian P Whitelegge; Jiyong Park; Minglei Zhao; Anna Pensalfini; Angela B Soriaga; Meytal Landau; Poh K Teng; Duilio Cascio; Charles Glabe; David Eisenberg
Journal:  Science       Date:  2012-03-09       Impact factor: 47.728

2.  Toxic fibrillar oligomers of amyloid-β have cross-β structure.

Authors:  James C Stroud; Cong Liu; Poh K Teng; David Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

Review 3.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

4.  Polymorphic C-terminal beta-sheet interactions determine the formation of fibril or amyloid beta-derived diffusible ligand-like globulomer for the Alzheimer Abeta42 dodecamer.

Authors:  Buyong Ma; Ruth Nussinov
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

5.  Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-β resulting in neurodegeneration.

Authors:  Haim Belinson; Zehavit Kariv-Inbal; Rakez Kayed; Eliezer Masliah; Daniel M Michaelson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

6.  Polymorphic triple beta-sheet structures contribute to amide hydrogen/deuterium (H/D) exchange protection in the Alzheimer amyloid beta42 peptide.

Authors:  Buyong Ma; Ruth Nussinov
Journal:  J Biol Chem       Date:  2011-08-05       Impact factor: 5.157

7.  Protective spin-labeled fluorenes maintain amyloid beta peptide in small oligomers and limit transitions in secondary structure.

Authors:  Robin Altman; Sonny Ly; Silvia Hilt; Jitka Petrlova; Izumi Maezawa; Tamás Kálai; Kálmán Hideg; Lee-Way Jin; Ted A Laurence; John C Voss
Journal:  Biochim Biophys Acta       Date:  2015-09-14

8.  Design and Optimization of Anti-amyloid Domain Antibodies Specific for β-Amyloid and Islet Amyloid Polypeptide.

Authors:  Christine C Lee; Mark C Julian; Kathryn E Tiller; Fanling Meng; Sarah E DuConge; Rehana Akter; Daniel P Raleigh; Peter M Tessier
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

9.  Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways.

Authors:  Ali Reza A Ladiwala; Jonathan S Dordick; Peter M Tessier
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

Review 10.  Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Authors:  Hyunbum Jang; Laura Connelly; Fernando Teran Arce; Srinivasan Ramachandran; Ratnesh Lal; Bruce L Kagan; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2013-02-28       Impact factor: 3.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.